you arrive at the study centre on the day you are scheduled to join the trial. a member of the study team explains the purpose of the research, the procedures that will be performed, and the possible risks. you sign a consent form indicating that you understand and agree to participate.

your baseline information is recorded, including age, weight, medical history of congenital heart disease, and any current medications.

a physical examination is performed and vital signs such as heart rate, systolic and diastolic blood pressure are measured.

blood samples are taken for laboratory tests that include complete blood count, blood chemistry, and kidney function. a urine sample is also collected for analysis.

you are scheduled for a diagnostic or therapeutic percutaneous vascular procedure that will be used to manage your congenital heart disease.

any required fasting or medication adjustments are explained, and you are instructed to follow them before the procedure.

immediately before the vascular procedure, the study medication cangrelor tetrasodium is prepared as a solution for injection or infusion.

the dose is calculated based on your body weight in micrograms per kilogram (µg/kg). the medication is given by intravenous infusion, meaning it is delivered directly into a vein through a needle or catheter.

the infusion is started at the beginning of the procedure and continues continuously for the duration of the procedure. no additional doses are given after the procedure is completed.

while the infusion is running, your heart rate, blood pressure, and breathing are checked regularly.

the study staff observes you for any signs of bleeding, respiratory distress such as wheezing or shortness of breath, and for changes in urine output.

additional blood samples may be taken during the procedure to assess laboratory parameters.

after the infusion is stopped, you remain under observation for at least 72 hours from the start of the infusion.

during this period, vital signs continue to be measured, and repeat laboratory tests are performed to monitor blood counts, chemistry, and kidney function.

the study team records any bleeding events, need for blood product transfusion, new or worsening respiratory symptoms, and any adverse events such as decreased urine output.

at the end of the 72‑hour observation period, a final assessment is completed. this includes a physical exam, vital sign check, and final laboratory tests.

if no safety concerns are identified, you are discharged from the study centre with instructions for any follow‑up that may be required.